Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Eirini PapadopoulouNikolaos TsoulosKaterina TsantikidiVasiliki Metaxa-MariatouPinelopi Eleftheria StamouAthina Kladi-SkandaliEvgenia KapeniGeorgios TsaousisGeorge PentheroudakisDimitrios PetrakisDimitra Ioanna LampropoulouGerasimos AravantinosIoannis VarthalitisGeorge KesisisIoannis BoukovinasPavlos PapakotoulasNikolaos KatirtzoglouElias AthanasiadisFlora StavridiChristos ChristodoulouAnna KoumarianouYeşim EralpGeorge NasioulasPublished in: PloS one (2019)
This study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized treatment decision making. The use of new sensitive NGS techniques can reliably detect tumor-derived mutations in liquid biopsy and provide clinically relevant information both before and after targeted treatment in patients with NSCLC. Thus, it could aid physicians in treatment decision making in clinical practice.